Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 8/2/08  and contains information from public web pages and contributions from the ZoomInfo community.

Dr. Thomas M. Rinderknecht

Wrong Dr. Thomas M. Rinderknecht?
 
Background

Employment History

  • Partner
    Rinderknecht Klein & Stadelhofer
  • Senior Partner
    Rinderknecht Klein & Stadelhofer
  • Owner
    RKS Rinderknecht & Burger
  • Position
    Board Of Directors

Board Memberships and Affiliations

Education

  • law degrees
    University of Zurich
  • law degrees
    University of Munich
  • law degrees
    Switzerland
24 Total References
Web References
Glycart Biotechnology - Board of Directors
www.glycart.com, 12 June 2005 [cached]
Thomas M. Rinderknecht, PhD (non-exec. Director) is senior partner of law firm Rinderknecht Klein & Stadelhofer, Zurich.He holds a doctor iuris degree of the University of Zurich, studied law in Zurich and Munich, practiced since 1982 as lawyer in international law firms in Switzerland and the United States, served and/or serves on various boards of public and private companies in the fields of pharmaceutical, biotech, publishing, media, financing and other business areas.
The Compensation Committee, consisting of ...
www.sec.gov, 10 Oct 2003 [cached]
The Compensation Committee, consisting of Mr. Clark, Dr. Harrison and Dr. Thomas Rinderknecht (until his resignation from the board on December 13, 2002), met informally during 2002 with compensation actions being considered by the full Board.
...
No member of the Compensation Committee was, during the 2002 fiscal year or previously, an officer or employee of ANTARES PHARMA INC, nor did any member have any relationship or transaction with us which is required to be reported under Item 402(k) or Regulation S-K under the Securities Exchange Act of 1934, as amended, except for Dr. Rinderknecht.Up until his resignation from our board on December 13, 2002, Dr. Rinderknecht served as a member of our Compensation Committee and his law firm, Rinderknecht, Klein & Stadelhofer, of which he is a principle, also served as legal adviser on various matters.
...
The members of the Compensation Committee are James Clark, Roger Harrison and Dr. Thomas Rinderknecht (until his resignation from our board on December 13, 2002).
...
2002. Dr. Thomas Rinderknecht, one of our board members until his resignation on December 13, 2002, is a partner in the firm of Rinderknecht Klein and Stadelhofer.
Dr. Thomas ...
www.sec.gov, 14 May 2002 [cached]
Dr. Thomas Rinderknecht
...
Dr. Rinderknecht joined the Board of Directors in January 2001 and served on its Audit Committee.He has also been a director of Permatec since its founding in June 1997.Dr. Rinderknecht has been a partner in the firm of Rinderknecht Klein & Stadelhofer in Zurich, Switzerland since 1985 and has been practicing commercial law in Europe since 1982.He holds law degrees from the University of Zurich, Switzerland and the University of Munich, Germany. None of the above directors are related to one another or to any executive officers of our Company. Information Concerning the Board of Directors The Board of Directors met five times during 2001 and acted by written action two times during 2001.The Board of Directors has an Audit and a Compensation Committee. The Audit Committee consisted of Mr. Evenstad, Dr. Philippe Dro and Dr. Thomas Rinderknecht and met three times during 2001.
...
The Compensation Committee, consisting of Mr. Clark, Dr. Gonella and Dr. Rinderknecht, met informally during 2001 with compensation actions being considered by the full Board.
...
No member of the Compensation Committee was, during the 2001 fiscal year or previously, an officer or employee of ANTARES PHARMA INC /MN/, nor did any member have any relationship or transaction with ANTARES PHARMA INC /MN/ which is required to be reported under Item 402(k) or Regulation S-K under the Securities Exchange Act of 1934, as amended, except for Dr. Rinderknecht.Dr. Rinderknecht served as a member of both the Audit Committee and the Compensation Committee and his law firm, Rinderknecht, Klein & Stadelhofer, of which he is a principle, also served as legal adviser on various matters.ANTARES PHARMA INC /MN/ recognized expenses of $97,292 for services provided by Rinderknecht, Klein & Stadelhofer in 2001. REPORT OF THE AUDIT COMMITTEE The Audit Committee reviews our financial reporting process on behalf of the Board of Directors.The members of the Audit Committee are Mr. Kenneth Evenstad, Dr. Philippe Dro and Dr. Thomas Rinderknecht.
...
Dr. Thomas Rinderknecht
...
The members of the Compensation Committee are James Clark, Dr. Jacques Gonella and Dr. Thomas Rinderknecht.
...
Dr. Thomas Rinderknecht
...
Dr. Thomas Rinderknecht (8)
Kenneth Evanstad and Thomas ...
www.sec.gov, 21 Mar 2003 [cached]
Kenneth Evanstad and Thomas Rinderknecht resigned from the board of directors on August 30, 2002, and December 13, 2002, respectively.
...
The Compensation Committee, consisting of Mr. Clark, Dr. Harrison and Dr. Rinderknecht, met informally during 2002 with compensation actions being considered by the full Board.
...
No member of the Compensation Committee was, during the 2002 fiscal year or previously, an officer or employee of ANTARES PHARMA INC, nor did any member have any relationship or transaction with ANTARES PHARMA INC which is required to be reported under Item 402(k) of Regulation S-K under the Securities Exchange Act of 1934, as amended, except for Dr. Rinderknecht.Dr. Rinderknecht served as a member of both the Audit Committee and the Compensation Committee and his law firm, Rinderknecht, Klein & Stadelhofer, of which he is a principle, also served as legal advisor on various matters.
Dr. Thomas Rinderknecht 47 ...
www.sec.gov, 19 Sept 2002 [cached]
Dr. Thomas Rinderknecht 47 Dr. Rinderknecht joined the Board of Directors in January 2001 and serves on its Compensation Committee.He also served on the Audit Committee until March 14, 2002.He has also been a director of Permatec since its founding in June 1997.Dr. Rinderknecht has been a partner in the firm of Rinderknecht Klein & Stadelhofer in Zurich, Switzerland since 1985, and has been practicing commercial law in Europe since 1982.He holds law degrees from the University of Zurich, Switzerland and the University of Munich, Germany.
...
The Audit Committee, consisting of Mr. Evenstad, Dr. Philippe Dro and Dr. Thomas Rinderknecht met three times during 2001.
...
The Compensation Committee, consisting of Mr. Clark, Dr. Gonella and Dr. Rinderknecht, met informally during 2001 with compensation actions being considered by the full Board.
...
No member of the Compensation Committee was, during the 2001 fiscal year or previously, an officer or employee of ANTARES PHARMA INC, nor did any member have any relationship or transaction with ANTARES PHARMA INC which is required to be reported under Item 402(k) of Regulation S-K under the Securities Exchange Act of 1934, as amended, except for Dr. Rinderknecht.Dr. Rinderknecht served as a member of both the Audit Committee and the Compensation Committee and his law firm, Rinderknecht, Klein & Stadelhofer, of which he is a principle, also served as legal advisor on various matters.ANTARES PHARMA INC recognized expenses of $97,292 for services provided by Rinderknecht, Klein & Stadelhofer in 2001. Section 16(a) Beneficial Ownership Reporting Compliance Section 16 (a) of the Securities Exchange Act of 1934 requires the Company's directors, certain officers and persons who own more than ten percent of a registered class of ANTARES PHARMA INC's equity securities, to file reports of ownership on Form 3 and changes in ownership on Forms 4 or 5 with the SEC.Such officers, directors and ten percent shareholders are also required by the SEC's rules to furnish ANTARES PHARMA INC with copies of all Section 16(a) reports they file. Specific due dates for such reports have been established by the SEC and ANTARES PHARMA INC is required to disclose any failure to file reports by such dates.Based solely on a review of the copies of such reports received by ANTARES PHARMA INC or by written representations from certain reporting persons, ANTARES PHARMA INC believes that during the year ended December 31, 2001, all Section 16(a) filing requirements applicable to officers, directors and ten percent shareholders were met.
Other People with the name "Rinderknecht":
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.
zirhbt201304